A NTIPARKINSONIAN drug trials have mainly focused on the substitution of the nigrostriatal dopaminergic deficit and have mainly resulted in improvement of parkinsonian motor symptoms. But insidious deteriorating neurodegeneration also affects other neurotransmitter systems and extranigral anatomical structures in patients with idiopathic Parkinson disease (PD). 1 Thus, the neurodegenerative process causes onset of a wide heterogeneous variety of parkinsonian features, all of which limit quality of life. 2 Therefore, compounds with a complex pharmacological profile, which also influences neurotransmission beyond the dopaminergic system, may hypothetically provide an additional therapeutic benefit in patients with PD. Budipine represents such a drug, because it also influences, for instance, GABAergic, norepinephrinergic, serotoninergic, and cholinergic neurotransmission.
3-7 Eltze 8 provides a review. Previous clinical trials [9] [10] [11] [12] have demonstrated the therapeutic efficacy of budipine on motor symptoms in subjects with PD who receive an insufficient antiparkinsonian drug regimen. Przuntek and Mü ller 13 provide a review. The objective of this multicenter, placebo-controlled, double-blind clinical trial was to demonstrate the antiparkinsonian efficacy of budipine in addition to a stable, prior, optimally titrated dopaminergic drug regimen consisting of a combination of levodopa and a dopa decarboxylase inhibitor, bromocriptine mesylate, and optional selegiline hydrochloride.
RESULTS
There was a significant distinct reduction of the CURS sum score in the budipinetreated patients compared with the placebotreated patients ( Table 2 and Figure 2 ). The improvement of the median CURS score corresponded to nearly 40% in the budipinetreated group. Columbia University Rating Scale subscores of tremor, rigidity, and akinesia were significantly more reduced in the budipine-than the placebo-treated subjects (Table 2) . Scores for depression and dementia did not significantly change within and between both groups (P=.12 and .29, respectively; Wilcoxon rank sum test). Dizziness (n=4), dry mouth (n=4), loss of appetite (n=3), nervousness (n=3), and visual dysfunction (n = 3) were reported adverse effects of the budipine-treated patients, whereas only 1 participant in the pla-
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cebo-treated group complained of dizziness. There were no clinically relevant changes for blood variables, blood pressure, heart rate, and electrocardiographic results (data not shown).
COMMENT
Additional treatment with budipine in doses up to 20 mg 3 times daily significantly further improved parkinsonian symptoms compared with placebo in our trial. We confirm the results of another double-blind placebocontrolled study on the efficacy of budipine, 20 mg administered in the morning. This study showed a significant decrease of the CURS sum score and amelioration of rigidity, akinesia, and tremor in 29 patients undergoing levodopa and benserazide monotherapy. Two dropouts appeared in this earlier study. 9 Previous open-label monocenter trials 9, 12 described the tremorlytic efficacy of budipine with additionally performed long-term electromyographic recordings in 20 patients with PD (11 patients in one trial and 9 in another). Our results also confirm those of earlier predominantly open-label and retrospective studies on subjects with PD without a previous stable drug regimen and with an insufficiently titrated dopaminergic antiparkinsonian drug regimen. Przuntek and Mü ller 13 provide a review. In contrast to those earlier studies, we used a higher dose of budipine, 20 mg 3 times daily, and titrated with certain selected dopaminergic drugs to an optimum response. Finally, our participants were enrolled in the study after receiving a stable dopaminergic drug regimen for 4 weeks. Despite this complex design, the addition of budipine further reduced parkinsonian symptoms. Therefore, we hypothesize that budipine, with its complex pharmacological profile, also influenced altered 
PATIENTS AND METHODS

PATIENTS
We enrolled 99 patients with idiopathic PD, according to the United Kingdom Brain Bank criteria, into the study (Figure 1 ). 14 Their drug regimen had to consist of a combination of levodopa/a dopa decarboxylase inhibitor, bromocriptine, and optional selegiline. Their Columbia University Rating Scale (CURS) score at study enrollment had to be between 24 and 50. 15 Subjects with severe unpredictable motor fluctuations; clinically relevant cardiac, hepatic, gastrointestinal, metabolic, renal, allergic, or psychiatric disorders; and/or intake of drugs that affect the dopaminergic system were not allowed to participate. Eighty-four patients finished the trial. We excluded 15 individuals (before unblinding) from the per-protocol analysis because of either premature termination not related to study medication (5 [10%] of budipine-treated patients and 2 [4%] of placebo-treated participants) or a major protocol violation (4 [8%] of budipine-treated individuals and 4 [8%] of placebo-treated subjects). There were no clinically relevant differences for the demographic data and clinical characteristics between both groups at baseline ( Table 1) .
DESIGN
We titrated the preexisting dopaminergic drug regimen to its optimum efficacy and tolerability (eg, onset of dyskinesia, vivid dreams, and cognitive deficits) according to the patients' and treating physicians' opinion within 4 weeks. Then, we kept the antiparkinsonian therapy stable for at least 4 weeks. A further 4-week screening period followed. Next, we slowly started titration of budipine from the initial application of 20 mg/d up to 60 mg/d, adding 10 mg/wk (Figure 2) . Soon after that, participants took budipine, 20 mg 3 times daily, until the end of the trial for 11 weeks. We allowed reduction of budipine to 40 mg/d because of the onset of adverse effects. One blinded investigator determined the score of the patients. Another blinded independent physician controlled patients' compliance, safety, and tolerability of budipine.
STATISTICAL ANALYSIS
We computed differences of the CURS score and its sub- (Figure 2) . 15, 16 (V indicates visit; subscript numbers, number of the visit.) Then, we used the Wilcoxon rank sum test for comparison of both treatment arms. The P value was adjusted to .01 for multiple testing of CURS and its subscores.
nondopaminergic systems in a positive manner and, therefore, caused this additional therapeutic benefit. The adverse effects of this drug were clear and were much more present. Therefore, the blinding of the investigators is at least uncertain in some patients. This could have biased our results to a certain extent, despite the use of 2 different investigators, one only for scoring and a second for further assessments. Both investigators were blinded to each other.
In conclusion, our study demonstrates that budipine, 20 mg 3 times daily, provides an additional therapeutic benefit because of its hypothetic positive impact on altered nondopaminergic neurotransmission in patients with PD. 
